Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Vitamin D Analogs for the Treatment of Secondary Hyperparathyroidism

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Calcitriol controls parathyroid gland (PTG) growth and suppresses the synthesis and secretion of PTH. However, because of its potent effects on intestinal calcium and phosphorus absorption and bone mobilization, calcitriol treatment can induce hypercalcemia and hyperphosphatemia often precluding its use at therapeutic doses. In the past decade, several vitamin D analogs have been developed. These analogs retain the action on the PTG while having less effect on calcium and phosphorus. Most of these analogs for the treatment of secondary hyperparathyroidism (SH) have a modification on the side chain of calcitriol. In the USA, two vitamin D analogs 19-nor 1,25(OH)<sub>2</sub>D<sub>2</sub> and 1α(OH)D<sub>2</sub> are currently used for the treatment of SH. Studies in animals demonstrated that 19-nor-1,25(OH)<sub>2</sub>D<sub>2</sub> is less calcemic and phosphatemic than 1α(OH)D<sub>2</sub>. The lower Ca × P product in 19-nor-1,25(OH)<sub>2</sub>D<sub>2</sub>-treated rats may be an important consideration in patient therapy. Further studies in patients are necessary to define these differences.

          Related collections

          Author and article information

          Journal
          BPU
          Blood Purif
          10.1159/issn.0253-5068
          Blood Purification
          S. Karger AG
          978-3-8055-7372-6
          978-3-318-00813-5
          0253-5068
          1421-9735
          2002
          2002
          17 January 2002
          : 20
          : 1
          : 109-112
          Affiliations
          Washington University School of Medicine, Renal Division, St. Louis, Mo., USA
          Article
          46993 Blood Purif 2002;20:109–112
          10.1159/000046993
          11803167
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 3, References: 15, Pages: 4
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/46993
          Categories
          Paper

          Comments

          Comment on this article